APA

von Hagens C., Walter-Sack I., Goeckenjan M., Osburg J., Storch-Hagenlocher B., Sertel S., Elsässer M., Remppis B. A., Edler L., Munzinger J., Efferth T., Schneeweiss A. & Strowitzki T. (20180320). Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). : Breast cancer research and treatment.

Chicago

von Hagens Cornelia, Walter-Sack Ingeborg, Goeckenjan Maren, Osburg Julia, Storch-Hagenlocher Brigitte, Sertel Serkan, Elsässer Michael, Remppis Bjoern Andrew, Edler Lutz, Munzinger Judith, Efferth Thomas, Schneeweiss Andreas and Strowitzki Thomas. 20180320. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). : Breast cancer research and treatment.

Harvard

von Hagens C., Walter-Sack I., Goeckenjan M., Osburg J., Storch-Hagenlocher B., Sertel S., Elsässer M., Remppis B. A., Edler L., Munzinger J., Efferth T., Schneeweiss A. and Strowitzki T. (20180320). Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). : Breast cancer research and treatment.

MLA

von Hagens Cornelia, Walter-Sack Ingeborg, Goeckenjan Maren, Osburg Julia, Storch-Hagenlocher Brigitte, Sertel Serkan, Elsässer Michael, Remppis Bjoern Andrew, Edler Lutz, Munzinger Judith, Efferth Thomas, Schneeweiss Andreas and Strowitzki Thomas. Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2). : Breast cancer research and treatment. 20180320.